GenSight Biologics S.A. GSGTF

GSGTF Company Overview

GenSight Biologics S.A. is a French biotechnology company focused on developing gene therapies and neuroprotective treatments for neurodegenerative diseases affecting the retina and central nervous system. The company operates primarily within the biotechnology and ophthalmology sectors, with a strategic emphasis on mitochondrial and retinal disorders that currently have limited therapeutic options. Its lead programs have centered on inherited retinal diseases, particularly Leber hereditary optic neuropathy (LHON), using adeno-associated virus (AAV)-based gene therapy platforms and mitochondrial targeting technologies.

The company’s principal revenue and value drivers have historically been tied to the development and potential commercialization of investigational therapies, research collaborations, and intellectual property associated with ophthalmic gene therapy. GenSight Biologics was founded in 2012 and emerged from research conducted at the Vision Institute in Paris and related academic institutions specializing in retinal disease and mitochondrial dysfunction. Over time, the company expanded from early-stage translational research into multinational clinical development activities, including regulatory engagement in Europe and other markets. Public disclosures in SEC filings and company investor materials indicate that GenSight has positioned itself as a specialist developer of therapies for rare ophthalmic diseases, leveraging orphan-drug pathways and targeted gene delivery technologies.